Effect of the Hill coefficient on estimates of <i>ε</i>_max (left column) and IC₅₀ (right column) for the logistic model with drug applied to the growth rate <... by Hope Murphy (8843516)

Partial correlation of <i>ε</i>_max (left column) and IC₅₀ (right column) estimates at 10 days and 20 days (first and second bar of each color, respectively) o... by Hope Murphy (8843516)

Mean and standard deviation of the signals in the left and right liver lobe for b = 50 and b = 800 s/mm², normalized to the monopolar signal at b = 50 s/mm² i... by Tobit Führes (12647099)

The detailed information of components identified in <i>Nanocnide lobata</i> based on UPLC-MS. by Yanlin Zou (12415810)

Subjects:

Longer polyQ sequences decrease the nuclear localization of AR in the absence of hormone. by Carlos M. Roggero (11909585)

Fig 2 - by Nida Mansoora (11648641)

Subjects:

Fig 3 - by Nida Mansoora (11648641)

Subjects:

Fig 4 - by Nida Mansoora (11648641)

Subjects:

Fig 1 - by Nida Mansoora (11648641)

Subjects:

Effect of different treatments on ionic contents like sodium, calcium, potassium, phosphorous and soluble proteins constituents of two wheat genotypes (Markaz 19 and Ujala 16) afte... by Nida Mansoora (11648641)

Subjects:

Participants with virologic suppression or failure at week 24. by Tosi M. Mwakyandile (16408705)

Subjects:

Socio-demographic and clinical characteristics of HIV-infected treatment-naïve individuals initiating ART. by Tosi M. Mwakyandile (16408705)

Subjects:

Consolidated Standards of Reporting Trials flow diagram for participants in the trial. by Tosi M. Mwakyandile (16408705)

Subjects:

Changes in baseline CD4 count through week 12 and week 24 according to the linear regression model. by Tosi M. Mwakyandile (16408705)

Subjects:

Most frequently experienced adverse events among study participants by treatment arms from baseline through week 24. by Tosi M. Mwakyandile (16408705)

Subjects:

Cumulative incidence of mortality and loss to follow-up (LTF) among study participants by treatment arms from baseline through week 24. by Tosi M. Mwakyandile (16408705)

Subjects:

Cumulative incidence of morbidity, loss to follow-up (LTF) and mortality among study participants by treatment arms from baseline through week 24. by Tosi M. Mwakyandile (16408705)

Subjects:

Median changes in CD4 count, platelet activation, immune activation, and exhaustion markers from baseline through week 12 and week 24. by Tosi M. Mwakyandile (16408705)

Subjects:

Empirical Bayes estimates of parameter <i>μ</i>. by Guillaume Lingas (9955528)

Subjects:

Model building procedure. by Guillaume Lingas (9955528)

Subjects: